Insight Molecular Diagnostics Inc. IMDX PHARMA
Company Overview
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Why Investors Should Care
Revenue has grown at a 27.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $4.05M (+115.6% YoY); net profit $-50.22M.
- Trailing 12 Months Year-on-year growth — revenue -53.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 27.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 27.24% |
| 1 Year: | -53.90% |
Stock Price Performance
| 1 Year: | +74.29% |
| 6 Months: | -20.93% |
| 3 Months: | -25.35% |
| 1 Month: | -11.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 27.2% over 5 years.
CONS
- Trading 49.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMDX Insight Molecular Diagnostics Inc. PHARMA | 4.27 | -2.81 | $139.73M | 0.00% | - | - | 27.24% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.00K | 143.00K | 555.00K | 503.00K | 1.12M | 2.03M | 984.00K | 3.59M | 380.00K | 237.00K | 67.00K | 297.00K | 463.00K | 429.00K | 176.00K | 104.00K | 115.00K | 2.14M | 518.00K | 260.00K | 32.00K | 239.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -222.00K | -46.00K | - | 79.00K | -394.00K | -866.00K | - | 247.00K | 31.00K | -269.00K | 10.00K | 272.00K | 248.00K | 45.00K | 50.00K | 50.00K | 1.32M | 350.00K | 139.00K | 15.00K | 157.00K |
| Operating Income | -1.37M | -1.41M | -2.41M | -2.93M | -2.53M | -2.58M | -4.53M | -3.59M | -6.83M | -3.91M | -4.23M | -3.02M | -4.00M | -5.46M | -5.26M | -8.43M | -8.77M | -6.24M | -6.27M | -11.36M | -13.57M | -13.60M | -35.68M | -3.02M | -1.63M | -1.71M | 5.85M | -8.29M | -6.51M | -9.27M | -4.63M | -13.52M | -6.80M | -9.84M | -11.05M | -4.41M | -11.40M |
| Net Income | -1.37M | -1.41M | -2.42M | -2.93M | -2.54M | -2.60M | -4.70M | -3.80M | -6.91M | -3.78M | -4.50M | -2.97M | -3.86M | -5.38M | -5.22M | -7.73M | -9.11M | -6.78M | -6.31M | -3.92M | -10.49M | -13.80M | -35.88M | -10.29M | -8.30M | -9.33M | 3.03M | -8.33M | -6.49M | -9.13M | -4.53M | -13.49M | -6.67M | -9.74M | -10.85M | -4.29M | -11.26M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.11 | -1.48 | -1.62 | 0.40 | -1.07 | -0.81 | -1.13 | -0.36 | -0.98 | -0.26 | -0.30 | -0.34 | -0.12 | -0.31 |
| R&D Expense | 1.12M | 886.00K | 1.09M | 1.69M | 1.20M | 1.36M | 1.83M | 2.00M | 1.84M | 1.46M | 2.32M | 1.53M | 1.34M | 1.51M | 1.62M | 2.16M | 3.23M | 2.62M | 1.80M | 3.36M | 2.54M | 3.14M | 4.59M | 2.01M | 2.44M | 1.47M | 2.13M | 2.44M | 2.19M | 2.31M | 2.45M | 2.82M | 2.92M | 3.28M | 3.88M | 4.95M | 4.49M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 1.22M | 2.20M | 958.00K | 1.50M | 1.88M | 4.05M |
| Gross Profit | - | - | - | - | - | - | -639.00K | 1.42M | -18.00K | 413.00K | 740.00K | 2.30M |
| Operating Income | -4.97M | -8.72M | -11.14M | -18.85M | -15.20M | -22.24M | -29.71M | -53.73M | -18.00M | -25.14M | -61.04M | -51.12M |
| Net Income | -4.99M | -8.73M | -11.17M | -19.38M | -15.75M | -22.43M | -29.93M | -64.10M | -72.90M | -27.78M | -60.66M | -50.22M |
| Diluted EPS | - | - | - | - | - | - | - | - | -13.25 | -3.75 | -4.66 | -1.65 |
| R&D Expense | 3.96M | 4.53M | 5.68M | 7.17M | 6.51M | 6.79M | 9.80M | 5.04M | 7.30M | 9.29M | 9.84M | 15.90M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 12.73M | 14.45M | 10.22M | 9.52M | 39.86M | 55.42M | 159.56M | 100.09M | 74.89M | 35.08M | 25.76M |
| Total Equity | 3.62M | -1.07M | 10.42M | 9.86M | 4.40M | 3.42M | 30.84M | 33.48M | 65.22M | 34.29M | 20.47M | -12.27M | -31.46M |
| Cash & Equivalents | 101.00K | 257.00K | 8.00M | 10.17M | 7.60M | 8.03M | 22.07M | 7.14M | 32.95M | 19.99M | 9.43M | 8.64M | 11.58M |
| Long Term Debt | - | - | - | - | 1.87M | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 2.31M | 4.58M | 5.81M | 6.09M | 9.02M | 21.94M | 94.35M | 60.50M | 49.30M | 47.35M | 57.22M |
| Current Liabilities | - | - | 2.31M | 4.28M | 4.45M | 5.56M | 4.44M | 9.00M | 14.12M | 12.11M | 7.19M | 7.28M | 12.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.23M | -7.52M | -13.38M | -11.65M | -19.71M | -25.98M | -35.94M | -45.57M | -23.32M | -20.69M | -22.18M |
| Investing Cash Flow | - | 315.00K | -181.00K | 843.00K | -31.00K | -12.41M | -11.75M | -13.96M | -4.34M | -932.00K | -512.00K | -3.19M |
| Financing Cash Flow | - | 11.65M | 9.88M | 9.97M | 12.11M | 47.87M | 22.80M | 78.36M | 35.81M | 12.19M | 20.43M | 28.07M |
| Capital Expenditure | -9.00K | -500.00K | -106.00K | -91.00K | -31.00K | -918.00K | -1.23M | -2.25M | -4.34M | -281.00K | -516.00K | -3.19M |
| Free Cash Flow | - | -4.73M | -7.63M | -13.48M | -11.68M | -20.63M | -27.21M | -38.19M | -49.91M | -23.61M | -21.20M | -25.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | -52.5% | 64.6% | -1.9% | 27.5% | 39.3% | 56.7% |
| Operating Margin % | - | - | - | - | - | - | -2,443.3% | -2,444.3% | -1,878.6% | -1,672.4% | -3,245.1% | -1,260.8% |
| Net Margin % | - | - | - | - | - | - | -2,461.5% | -2,916.2% | -7,609.8% | -1,848.4% | -3,225.0% | -1,238.5% |
| ROE % | 464.2% | -83.9% | -113.2% | -440.0% | -460.2% | -72.7% | -89.4% | -98.3% | -212.6% | -135.7% | 494.2% | 159.6% |
| ROCE % | - | -83.7% | -109.5% | -327.1% | -384.2% | -62.8% | -64.0% | -36.9% | -20.5% | -37.1% | -219.5% | -373.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Broadwood Capital, Inc. | 38.76% | 12.68M | $50.74M |
| 2 | AWM Investment Company, Inc. | 8.67% | 2.84M | $11.35M |
| 3 | Vanguard Capital Management LLC | 2.25% | 735.85K | $2.94M |
| 4 | Pura Vida Investments, Llc | 1.48% | 484.85K | $1.94M |
| 5 | Family Office Research LLC | 1.13% | 368.85K | $1.48M |
| 6 | Geode Capital Management, LLC | 0.79% | 256.90K | $1.03M |
| 7 | FNY Investment Advisers, LLC | 0.56% | 182.56K | $730.24K |
| 8 | Jane Street Group, LLC | 0.48% | 157.68K | $630.73K |
| 9 | Blackrock Inc. | 0.46% | 150.52K | $602.08K |
| 10 | Vanguard Fiduciary Trust Co | 0.38% | 124.58K | $498.30K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMDX
iMDx executives are set to meet investors in New York - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOQWx3UmtiVWh0Wng0Y1BIbWlscEpjZVA3NDBIX3ctSXUyRWRzYUd4V3JCdTRHbk53cVNqTzNTczVSU3l4amtUOVJ0Y1dMUjl1RFE3SEtRWU12UTBJb3p4N213YlJpMzFYeWM1ZVQ5dXN2N0wwVmt2cjlJTFhFcmIxSXFzTDhCa1BGRVdxR1…
IMDX Sep 2026 5.000 call (IMDX260918C00005000) Stock Price, News, Quote & History - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTFBkWTBrRDRBbUsyenVZMnhtM2ZidGxLbFhZS3g4YS02THVBdk9JTkR5VWRQMlliaTBMTmlONWdTZm53bmhJX0F0NDlnWko0X3RZQUFOZTU1cmVfX08yRGhzYlJR?oc=5" target="_blank">IMDX Sep 2026 5.000 call (IMDX26091…
$IMDX stock is down 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNd0NxMVljc3Q5OG44OXlPVlpDejhfaGFkRnR5R3NWUVVickIySE5nXzNMYzZZTzV2Q21NcV9lNlpSd0pLQjExYUlQU1oybnBER0ZCa1ROSjJ3SVJ4SzNRckdHbUF3OEtoOU42TDJHdXdoUU1hd3FZbkZqTDlwR05lQXpfVmxHMmVNS21BTG…
Here's Why We're A Bit Worried About Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Situation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxPaDVkQ1F0RUhGVmJfQTdvZkViaVA1UDFiNWZUcm5lRzdXVDlwLTFyVDZmQUs1WFptYWFQWExoQk43cVlCME5DaElaOU9MdEtCQ3JKcndFN0dWZ3JEX3lTOG43bEZ5THl5dDJQV3BHRzhPcHM0R2FwaWQtRDlLdnoxZFlwdWRqcUtOSEotRW…
IMDX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE05MFJXemFhZ056ejN4ZkJxdzN5TXNqbDRDdEhXYXpRZmhVUGxYYVh0ZlRBd0U3djRteUtBQjh6OU84eGVKNFhNMVFaZkVVcWZRTm91TVRhTUx2MlVQV01QNk5HVUp3VUlnQ0tOOGs2OW8xQkY5czVwdlZ3?oc=5" target="_blank">IMD…
iMDx Announces $26.0 Million Registered Direct Offering - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQZFBQbEhFXzdSUHpLWU1JcFY1MjNNOXpQOHdRdzh4QzFnLUpsank2MkwyZVlPRG9sYk4ydWwwckxvajA2cWhvYWF0ZjF1djE4Mm8wY1p0YVlrNVkwdF9LTUxzT1NxaXFudjlNNTZzNEtIbERLdDN3X2FKUVJqcE0xQ05qZWtiU185UnpBMm…
IMDX — Frequently Asked Questions
What is the current share price of Insight Molecular Diagnostics Inc. (IMDX)?
As of 2026-09-19 21:16 PDT, Insight Molecular Diagnostics Inc. (IMDX) trades at $4.27 on NasdaqCM. Its 52-week range is $2.40 to $8.48.
What is the market capitalisation of IMDX?
Insight Molecular Diagnostics Inc. (IMDX) has a market capitalisation of $139.73M on NasdaqCM.
What is the P/E ratio of IMDX?
IMDX trades at a trailing price-to-earnings (P/E) ratio of -2.81. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -6.13.
Is IMDX a good stock to buy?
This page provides a data-driven analysis of Insight Molecular Diagnostics Inc. (IMDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.